FIELD: pharmaceutics.
SUBSTANCE: invention relates to the pharmaceutical industry and is a pharmaceutical formulation for the intranasal treatment of a human condition associated with vitamin B12 deficiency, where the composition contains vitamin B12 and a pharmaceutically acceptable carrier, and wherein vitamin B12 particles are dispersed in a hydrophobic dispersive phase, which is a pharmaceutically acceptable carrier.
EFFECT: invention provides high bioavailability and a decrease in colour intensity.
9 cl, 4 dwg, 2 ex
Authors
Dates
2018-05-29—Published
2013-11-28—Filed